Sentinel Oncology receives Innovate UK grant to develop new drugs for the treatment of glioblastoma multiforme
Sentinel Oncology is pleased to announce a recent award from Innovate UK
The recent grant award of £1.2m will fund the pre-clinical development of a new drug for the treatment of glioblastoma which is a CNS cancer with very high unmet need.
Bob Boyle, CEO of Sentinel Oncology said “Sentinel Oncology has a strong track record in the drug discovery and development field and this grant funding from Innovate UK will help further our strategy of developing drugs for rare and hard to treat diseases."
About Sentinel Oncology Limited
Sentinel Oncology was founded in 2005 in Cambridge, UK and is a drug discovery company dedicated to the development and commercialisation of new therapeutics to treat cancer patients for whom there is currently an unmet medical need.
The Sentinel Oncology portfolio includes a lead programme that has been licensed to Cascadian Inc. and a second programme which is at the candidate drug phase. We are further developing a suite of novel small molecules designed to enhance therapeutic index by delivering the effects of drugs directly to the tumour.
Sentinel oncology is a fully integrated drug discovery company seeking to develop high quality drug candidates for partnering with the biotechnology and pharmaceutical industry. Our strategy relies on seeking partners and collaborators to maximise the value of our programmes.
About Innovate UK
Innovate UK is part of UK Research and Innovation, a non-departmental public body funded by a grant-in-aid from the UK government.
For more information visit UK Research and Innovation’s website.
About the Biomedical Catalyst
The Biomedical Catalyst is a partnership between Innovate UK and the MRC. It supports the most innovative life sciences opportunities. Its aims are to de-risk innovative science and commercialise the ideas that come from academia and industry. It helps UK SMEs develop into competitive and sustainable businesses.